Tumor fibroblast–derived epiregulin promotes growth of colitis-associated neoplasms through ERK
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Molecular mechanisms specific to colitis-associated cancers have been poorly characterized. Using comparative whole-genome expression profiling, we observed differential expression of epiregulin (EREG) in mouse models of colitis-associated, but not sporadic, colorectal cancer. Similarly, EREG expression was significantly upregulated in cohorts of patients with colitis-associated cancer. Furthermore, tumor-associated fibroblasts were identified as a major source of EREG in colitis-associated neoplasms. Functional studies showed that Ereg-deficient mice, although more prone to colitis, were strongly protected from colitis-associated tumors. Serial endoscopic studies revealed that EREG promoted tumor growth rather than initiation. Additionally, we demonstrated that fibroblast-derived EREG requires ERK activation to induce proliferation of intestinal epithelial cells (IEC) and tumor development in vivo. To demonstrate the functional relevance of EREG-producing tumor-associated fibroblasts, we developed a novel system for adoptive transfer of these cells via mini-endoscopic local injection. It was found that transfer of EREG-producing, but not Ereg-deficient, fibroblasts from tumors significantly augmented growth of colitis-associated neoplasms in vivo. In conclusion, our data indicate that EREG and tumor-associated fibroblasts play a crucial role in controlling tumor growth in colitis-associated neoplasms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · cited 1×
“As the acquisition of a myofibroblastic phenotype is a common feature for tumor-associated fibroblasts (45), we analyzed the relationship between α-SMA–expressing fibroblasts and EREG expression in the AOM/DSS model.”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
Self-citationGrivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Terzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.058 · Cited by 1,974 · cited 1×
“Experimental data on molecular mechanisms that can modulate growth of CAC and sporadic CRC are increasing (8, 9).”
BackgroundA Dominant Mutation That Predisposes to Multiple Intestinal Neoplasia in the Mouse
Moser, A. R., Pitot, H. C., & Dove, W. F. (1990) · Science · doi:10.1126/science.2296722 · Cited by 1,591 · cited 1×
“For studies of sporadic tumorigenesis, the Apcmin/+ model was used (12).”
MethodErez, N., Truitt, M., Olson, P., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.041 · Cited by 1,515
Bollrath, J., Phesse, T. J., von Burstin, V. A., Putoczki, T., Bennecke, M., Bateman, T., Nebelsiek, T., Lundgren-May, T., Canli, Ö., Schwitalla, S., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.002 · Cited by 946 · cited 2×
“Several recent publications suggested that the inflammatory degree dictates the risk for colitis-associated tumor development (27, 28) Specifically, tumor development in the AOM/DSS model has been linked to STAT3 signaling in IEC induced by proinflammatory mediators such as IL-6 and IL-11 (29, 30).”
BackgroundSelf-citationModulation of the Intestinal Microbiota Alters Colitis-Associated Colorectal Cancer Susceptibility
Uronis, J. M., Mühlbauer, M., Herfarth, H. H., Rubinas, T. C., Jones, G. S., & Jobin, C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006026 · Cited by 425
Cited by
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
Self-citationSchwabe, R. F., & Jobin, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3610 · Cited by 1,689
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
Yap-dependent reprogramming of Lgr5+ stem cells drives intestinal regeneration and cancer
Gregorieff, A., Liu, Y., Inanlou, M. R., Khomchuk, Y., & Wrana, J. L. (2015) · Nature · doi:10.1038/nature15382 · Cited by 648
Cancer-associated fibroblasts in gastrointestinal cancer
Kobayashi, H., Enomoto, A., Woods, S. L., Burt, A. D., Takahashi, M., & Worthley, D. L. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0115-0 · Cited by 589
The Yin and Yang of Toll-like receptors in cancer
Pradere, J.-P., Dapito, D. H., & Schwabe, R. F. (2014) · Oncogene · doi:10.1038/onc.2013.302 · Cited by 331
Heichler, C., Scheibe, K., Schmied, A., Geppert, C. I., Schmid, B., Wirtz, S., Thoma, O.-M., Kramer, V., Waldner, M. J., Büttner, C., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319200 · Cited by 328
Self-citationCancer-promoting effects of microbial dysbiosis
Sheflin, A. M., Whitney, A. K., & Weir, T. L. (2014) · Current Oncology Reports · doi:10.1007/s11912-014-0406-0 · Cited by 301
Cytokines, IBD, and Colitis-associated Cancer
Francescone, R., Hou, V., & Grivennikov, S. I. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000236 · Cited by 272
Epiregulin: Roles in normal physiology and cancer
Riese, D. J., & Cullum, R. L. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.03.005 · Cited by 192
“Epiregulin may be involved in the paracrine regulation of colitis-associated neoplasms by the tumor stroma, as epiregulin expression and shedding by intestinal fibroblasts stimulate proliferation of adjacent intestinal epithelial cells and stimulate their development into tumor cells [82].”
BackgroundNowarski, R., Jackson, R., & Flavell, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.11.040 · Cited by 191
Bai, Y., Shang, K., Chen, H., Ding, F., Wang, Z., Liang, C., Xu, Y., Sun, M., & LI, Y. (2015) · Cancer Science · doi:10.1111/cas.12745 · Cited by 109
Fibroblasts as Modulators of Local and Systemic Cancer Metabolism
Sanford-Crane, H., Abrego, J., & Sherman, M. H. (2019) · Cancers · doi:10.3390/cancers11050619 · Cited by 77
“By testing candidate recombinant proteins, the authors found that the 3 EGFR ligands discussed above—BTC, HB-EGF, and EREG—as well as PTHrP all stimulate thermogenic gene expression in primary adipocytes.”
Background
Metadata
- Authors
- Neufert, C., Becker, C., Türeci, Ö., Waldner, M. J., Backert, I., Floh, K., Atreya, I., Leppkes, M., Jefremow, A., Vieth, M., Schneider-Stock, R., Klinger, P., Greten, F. R., Threadgill, D. W., Sahin, U., & Neurath, M. F.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-03-15
- Volume
- 123
- Issue
- 4
- Pages
- 1428-1443
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2119733047
- Cited by
- 115
- References
- 10
- FWCI
- 6.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.